BR112021023347A2 - Compostos de pirrolidina - Google Patents
Compostos de pirrolidinaInfo
- Publication number
- BR112021023347A2 BR112021023347A2 BR112021023347A BR112021023347A BR112021023347A2 BR 112021023347 A2 BR112021023347 A2 BR 112021023347A2 BR 112021023347 A BR112021023347 A BR 112021023347A BR 112021023347 A BR112021023347 A BR 112021023347A BR 112021023347 A2 BR112021023347 A2 BR 112021023347A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pyrrolidine compounds
- formula
- pyrrolidine
- nhso2nh
- Prior art date
Links
- 150000003235 pyrrolidines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
compostos de pirrolidina. a presente invenção refere-se a compostos da fórmula em que l é selecionados a partir do grupo consistindo em -ch2nhch2-, -ch2nh-, -nh-, -s-, -s(o)-, -s(o)2-, -o-, -och2-, -och2ch2o-, -nhso2nh-, e , ou um sal farmaceuticamente aceitável do mesmo; um composto da fórmula, processos para preparação dos compostos e seus sais, uma composição farmacêutica, e métodos de tratamento de pacientes que necessitam de tal tratamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382477 | 2019-06-07 | ||
| PCT/US2020/035825 WO2020247429A1 (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021023347A2 true BR112021023347A2 (pt) | 2022-04-12 |
Family
ID=66821161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023347A BR112021023347A2 (pt) | 2019-06-07 | 2020-06-03 | Compostos de pirrolidina |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11286249B2 (pt) |
| EP (1) | EP3980409A1 (pt) |
| JP (2) | JP6940717B2 (pt) |
| KR (3) | KR102477481B1 (pt) |
| CN (1) | CN114008021A (pt) |
| AU (1) | AU2020287599B2 (pt) |
| BR (1) | BR112021023347A2 (pt) |
| CA (1) | CA3140869A1 (pt) |
| CL (1) | CL2021003202A1 (pt) |
| CO (1) | CO2021016295A2 (pt) |
| CR (1) | CR20210602A (pt) |
| DO (1) | DOP2021000254A (pt) |
| EA (1) | EA202193007A1 (pt) |
| EC (1) | ECSP21088515A (pt) |
| IL (1) | IL288174A (pt) |
| JO (1) | JOP20210319A1 (pt) |
| MA (1) | MA56115A (pt) |
| MX (1) | MX2021014913A (pt) |
| PE (1) | PE20220134A1 (pt) |
| SG (1) | SG11202113244UA (pt) |
| WO (1) | WO2020247429A1 (pt) |
| ZA (1) | ZA202109251B (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022381258A1 (en) | 2021-11-03 | 2024-05-02 | Tuojie Biotech (Shanghai) Co., Ltd. | Substituted phenylpropionic acid derivative and use thereof |
| WO2023146785A1 (en) | 2022-01-26 | 2023-08-03 | Eli Lilly And Company | Pyrrolidine compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003016265A1 (ja) * | 2001-08-17 | 2004-12-02 | エーザイ株式会社 | 環状化合物およびｐｐａｒアゴニスト |
| EP1701931B1 (en) | 2003-12-24 | 2018-10-10 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| AU2003300438A1 (en) | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
-
2020
- 2020-06-03 JP JP2021505713A patent/JP6940717B2/ja active Active
- 2020-06-03 AU AU2020287599A patent/AU2020287599B2/en active Active
- 2020-06-03 US US17/056,144 patent/US11286249B2/en active Active
- 2020-06-03 KR KR1020217040065A patent/KR102477481B1/ko active IP Right Grant
- 2020-06-03 PE PE2021002037A patent/PE20220134A1/es unknown
- 2020-06-03 MX MX2021014913A patent/MX2021014913A/es unknown
- 2020-06-03 KR KR1020247002433A patent/KR20240014618A/ko active Application Filing
- 2020-06-03 EP EP20747210.1A patent/EP3980409A1/en active Pending
- 2020-06-03 JO JOP/2021/0319A patent/JOP20210319A1/ar unknown
- 2020-06-03 CN CN202080041924.XA patent/CN114008021A/zh active Pending
- 2020-06-03 BR BR112021023347A patent/BR112021023347A2/pt unknown
- 2020-06-03 MA MA056115A patent/MA56115A/fr unknown
- 2020-06-03 EA EA202193007A patent/EA202193007A1/ru unknown
- 2020-06-03 WO PCT/US2020/035825 patent/WO2020247429A1/en active Application Filing
- 2020-06-03 KR KR1020227043106A patent/KR102629923B1/ko active IP Right Grant
- 2020-06-03 CA CA3140869A patent/CA3140869A1/en active Pending
- 2020-06-03 CR CR20210602A patent/CR20210602A/es unknown
- 2020-06-03 SG SG11202113244UA patent/SG11202113244UA/en unknown
-
2021
- 2021-09-02 JP JP2021143227A patent/JP2021191784A/ja active Pending
- 2021-11-16 IL IL288174A patent/IL288174A/en unknown
- 2021-11-18 ZA ZA2021/09251A patent/ZA202109251B/en unknown
- 2021-11-30 CO CONC2021/0016295A patent/CO2021016295A2/es unknown
- 2021-12-01 CL CL2021003202A patent/CL2021003202A1/es unknown
- 2021-12-07 DO DO2021000254A patent/DOP2021000254A/es unknown
- 2021-12-07 EC ECSENADI202188515A patent/ECSP21088515A/es unknown
-
2022
- 2022-02-15 US US17/671,806 patent/US20220169636A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20220134A1 (es) | 2022-01-27 |
| KR20240014618A (ko) | 2024-02-01 |
| JP2021191784A (ja) | 2021-12-16 |
| CN114008021A (zh) | 2022-02-01 |
| KR102629923B1 (ko) | 2024-01-30 |
| MA56115A (fr) | 2022-04-13 |
| JP2021524498A (ja) | 2021-09-13 |
| KR20230004890A (ko) | 2023-01-06 |
| AU2020287599B2 (en) | 2023-10-19 |
| JOP20210319A1 (ar) | 2023-01-30 |
| AU2020287599A1 (en) | 2022-01-06 |
| ECSP21088515A (es) | 2022-01-31 |
| US11286249B2 (en) | 2022-03-29 |
| US20210253559A1 (en) | 2021-08-19 |
| WO2020247429A1 (en) | 2020-12-10 |
| EA202193007A1 (ru) | 2022-03-25 |
| EP3980409A1 (en) | 2022-04-13 |
| ZA202109251B (en) | 2024-04-24 |
| CO2021016295A2 (es) | 2021-12-10 |
| CL2021003202A1 (es) | 2022-09-09 |
| DOP2021000254A (es) | 2022-01-16 |
| KR20220018494A (ko) | 2022-02-15 |
| CA3140869A1 (en) | 2020-12-10 |
| JP6940717B2 (ja) | 2021-09-29 |
| CR20210602A (es) | 2022-01-06 |
| US20220169636A1 (en) | 2022-06-02 |
| SG11202113244UA (en) | 2021-12-30 |
| IL288174A (en) | 2022-01-01 |
| KR102477481B1 (ko) | 2022-12-15 |
| MX2021014913A (es) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| BR112022026899A2 (pt) | Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório | |
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| BR112022019557A2 (pt) | Inibidores de replicação de norovírus e coronavírus | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| BR112018067930A8 (pt) | Composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto. | |
| BR112019024831A2 (pt) | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112018010962A8 (pt) | Composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto | |
| BR112018015289A2 (pt) | compostos de benzopirazol e análogos dos mesmos | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| EA201500265A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
| BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
| BRPI0519058A2 (pt) | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto | |
| BR112023002573A2 (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral | |
| BR112018073524A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição. | |
| BR112018016349A2 (pt) | métodos para tratamento e profilaxia de hiv e aids | |
| BR112021023347A2 (pt) | Compostos de pirrolidina | |
| BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112021019817A2 (pt) | Compostos de pirrol | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos |